Irinotecan Sun

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Sun, is a topoisomerase I inhibitor presented as a sterile injectable formulation for intravenous use. It treats metastatic colorectal cancer and colorectal adenocarcinoma in adult patients.

GNH USA supplies Irinotecan Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Sun is employed in the management of colorectal cancer and related disease stages.

- Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy regimens. - Colorectal adenocarcinoma: enhances tumor response rates as part of standard treatment protocols. - Advanced colorectal cancer: provides disease control in patients who have progressed on prior therapies.

Irinotecan is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often delayed and may be severe. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized tiredness affecting daily activities. - Abdominal pain: discomfort in the stomach region.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe (grade 3‑4) diarrhea: can lead to dehydration and electrolyte imbalance. - Cholinergic syndrome: sweating, lacrimation, and bradycardia. - Allergic reactions: rash, urticaria, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Bone marrow suppression: pancytopenia affecting multiple blood cell lines.

Prior to initiating Irinotecan therapy, several safety considerations are recommended.

- Monitor blood counts: perform regular CBC to detect neutropenia and anemia. - Assess liver function: adjust dosing in patients with hepatic impairment. - Evaluate renal function: consider dose modification for severe renal insufficiency. - Review concomitant medications: avoid strong CYP3A4 or UGT1A1 inhibitors. - Patient education: instruct on early signs of diarrhea and infection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan may interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia. - Concurrent use with other topoisomerase I inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely): - Myelosuppressive agents (e.g., carboplatin): enhance bone‑marrow suppression. - Anticholinergic drugs (e.g., atropine): may mask cholinergic syndrome. - Warfarin: monitor INR as irinotecan can affect coagulation parameters.